The Emirates Drug Establishment (EDE) has signed a landmark Memorandum of Understanding (MoU) with the Korean Ministry of Food and Drug Safety to enhance collaboration in pharmaceutical manufacturing and medical products.
The MoU, inked in Korea, aims to streamline the exchange of expertise in drug regulation, clinical trials, and pharmacovigilance between the UAE and Korea.
The agreement was signed by Dr. Fatima Mohammed Al Kaabi, Director-General of EDE, and Joon-Su Shin, General Director at the Korean Ministry of Food and Drug Safety. Key officials from both nations were present at the ceremony.
A key aspect of the MoU is the introduction of a fast-track approval process for pharmaceutical products already endorsed by international regulatory bodies. This initiative is expected to accelerate the availability of innovative treatments in both countries, benefiting patients and enhancing healthcare outcomes.
Post-marketing surveillance will also be strengthened under the agreement, with mechanisms to detect counterfeit or defective medical products, ensuring swift action to protect public health. The collaboration further includes the exchange of clinical trial results, promoting joint scientific and technological research.
The partnership also focuses on training programs and field visits, aimed at improving the capabilities of pharmaceutical professionals in both nations, with an emphasis on implementing Good Clinical and Manufacturing Practices (GCP and GMP).
Dr. Al Kaabi highlighted the strategic importance of the MoU, noting that it aligns with the UAE’s vision of expanding international partnerships in healthcare to improve access to safe and innovative medicines while fostering sustainable health advancements.
News Source: Emirates News Agency
